A 2024 clinical trial investigating the neo-adjuvant humanized antibody Zilovertamab for targeting a constitutively active receptor tyrosine kinase in breast cancer cells was initially set to measure ALDH1 and CD133, BCSC surface markers, according to ClinicalTrials.gov. The gene discussed is ALDH1A1; the disease is breast cancer.